Physician profile
Edward C Dow
NPI 1437131000
$1,472.29
in general payments reported to CMS, 2019-2025
21 companies · $15.73 in 2025
The $15.73 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $151 · 2021: $113 · 2022: $55.86 · 2023: $162 · 2024: $143 · 2025: $15.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206 · Education: $99.99 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.73 |
| Education | $99.99 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $251.95 | 2019 | |
| Janssen Biotech, INC. | $227.08 | 2019-2023 | Darzalex |
| Eisai INC. | $166.76 | 2019-2023 | |
| Smith+Nephew, INC. | $142.77 | 2024 | Oasis, Stravix, Grafix |
| Jazz Pharmaceuticals INC. | $113.41 | 2021 | |
| Genentech USA, INC. | $71.81 | 2019 | |
| Octapharma USA, INC. | $64.21 | 2019-2020 | |
| Pfizer INC. | $57.80 | 2019 | |
| Adc Therapeutics America, INC. | $55.86 | 2022 | |
| Exelixis INC. | $54.61 | 2019 | |
| Incyte Corporation | $36.24 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $32.53 | 2019 | |
| Mylan Institutional INC. | $30.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.30 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $23.50 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $22.87 | 2019 | |
| Seagen INC. | $21.46 | 2019 | |
| Celgene Corporation | $19.74 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.45 | 2019 | |
| Astellas Pharma US INC | $16.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.73 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Dow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.